TCRR
Morgan Stanley’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-155,390
| Closed | -$233K | – | 7779 |
|
|
2023
Q1 | $233K | Buy |
155,390
+108,995
| +235% | +$163K | ﹤0.01% | 5641 |
|
|
2022
Q4 | $46.3K | Sell |
46,395
-26,853
| -37% | -$26.8K | ﹤0.01% | 6326 |
|
|
2022
Q3 | $131K | Sell |
73,248
-76,335
| -51% | -$137K | ﹤0.01% | 5942 |
|
|
2022
Q2 | $434K | Sell |
149,583
-137,819
| -48% | -$400K | ﹤0.01% | 5489 |
|
|
2022
Q1 | $794K | Sell |
287,402
-160,928
| -36% | -$445K | ﹤0.01% | 5132 |
|
|
2021
Q4 | $2.09M | Buy |
448,330
+318,953
| +247% | +$1.49M | ﹤0.01% | 4552 |
|
|
2021
Q3 | $1.1M | Sell |
129,377
-27,203
| -17% | -$232K | ﹤0.01% | 4990 |
|
|
2021
Q2 | $2.57M | Buy |
156,580
+155,079
| +10,332% | +$2.55M | ﹤0.01% | 4445 |
|
|
2021
Q1 | $33K | Sell |
1,501
-19,821
| -93% | -$436K | ﹤0.01% | 6552 |
|
|
2020
Q4 | $659K | Buy |
21,322
+17,477
| +455% | +$540K | ﹤0.01% | 4908 |
|
|
2020
Q3 | $78K | Sell |
3,845
-136,269
| -97% | -$2.76M | ﹤0.01% | 5540 |
|
|
2020
Q2 | $2.15M | Buy |
140,114
+133,630
| +2,061% | +$2.05M | ﹤0.01% | 3521 |
|
|
2020
Q1 | $50K | Sell |
6,484
-15,734
| -71% | -$121K | ﹤0.01% | 5467 |
|
|
2019
Q4 | $317K | Buy |
22,218
+18,342
| +473% | +$262K | ﹤0.01% | 5177 |
|
|
2019
Q3 | $59K | Buy |
3,876
+3,823
| +7,213% | +$58.2K | ﹤0.01% | 5652 |
|
|
2019
Q2 | $1K | Sell |
53
-819
| -94% | -$15.5K | ﹤0.01% | 6589 |
|
|
2019
Q1 | $15K | Buy |
+872
| New | +$15K | ﹤0.01% | 6097 |
|